TAKEUCHI Masayoshi

Researcher Profile & Settings

Research

Overview of research:
Involvement of toxic AGEs (TAGE) as new targets in the onset and progression of the lifestyle-related disease and inhibition thereof.

Special Field

• Medical, Dental, and Pharmaceutical Science

Education

• Hokuriku University Graduate School
• Hokuriku University Faculty of Pharmaceutical Science

Degree

• Doctor of Pharmacy

Academic & Professional Experience

• Apr. 2011Medical Research Institute, Kanazawa Medical University Professor

Research Activities

Published Papers

• Potential of an interorgan network mediated by toxic advanced glycation end-products in a rat model, Shinya Inoue, Takanobu Takata, Yusuke Nakazawa, Yuka Nakamura, Xin Guo, Sohsuke Yamada, Yasuhito Ishigaki, Masayoshi Takeuchi, Katsuhito Miyazawa, Nutrients, 13:80, 2020
• Exploration of the mystery of the third glycogen metabolite 1,5-anhydro-D-fructose (1,5-AF), Akiko Sakasai-Sakai, Takanobu Takata, Hirokazu Suzuki, Ikuro Maruyama, Kenji Tanaka, Yoshihiro Motomiya, Masayoshi Takeuchi, The Journal of Japan Mibyou Association, 26:67-72, Jan. 2020
• Impact of intracellular glyceraldehyde-derived advanced glycation end-products on human hepatocyte cell death, Akiko Sakasai-Sakai, Takanobu Takata, Jun-ichi Takino, Masayoshi Takeuchi, 7:1, Oct. 2017
• Toxic AGEs (TAGE) theory: a new concept for preventing the development of diseases related to lifestyle, Takeuchi M, Diabetology & Metabolic Syndrome, 12:105, Nov. 2020
• Intracellular toxic advanced glycation end-products promote the production of reactive oxygen species in HepG2 cells, Sakasai-Sakai A, Takata T, Takeuchi M, International Journal of Molecular Sciences, 21:4861, Jul. 2020
• The effect of glyceraldedehyde-derived advanced glycation end products on β-tublin-inhibited neurite outgrowth in SH-SY5Y human neuroblastoma cells, (Nasu R), Furukawa A, Suzuki K, Takeuchi M, Koriyama Y, Nutrients, 12:2958, Sep. 2020
• Impact of intracellular toxic advanced glycation end-products (TAGE) on murine myoblast cell death, Takata Takanobu, Sakasai-Sakai Akiko, Takeuchi Masayoshi, Diabetology & Metabolic Syndrome, 12:54, Jun. 2020
  DOI:10.1186/s13098-020-00561-z
• Intracellular toxic advanced glycation end-products in cardiomyocytes may cause cardiovascular disease, Takata Takanobu, Sakasai-Sakai Akiko, Ueda Tadashi, Takeuchi Masayoshi, Scientific Reports, 9:2121, Feb. 2019
  DOI:10.1038/s41598-019-39202-5
• Evidence for toxic advanced glycation end-products generated in the normal rat liver, Takata Takanobu, Sakasai-Sakai Akiko, Takino Jun-ichi, Takeuchi Masayoshi, Nutrients, 11:1612, Jul. 2019
  DOI:10.3390/nu11071612
• The relevance of toxic AGEs (TAGE) cytotoxicity to NASH pathogenesis: A mini-review, Sakasai-Sakai Akiko, Takata Takanobu, Takino Jun-Ichi, Takeuchi Masayoshi, Nutrients, 11:462, Feb. 2019
  DOI:10.3390/nu11020462
• Immunological evidence for in vivo production of novel advanced glycation end-products from 1,5-anhydro-D-fructose, a glycogen metabolite, Sakasai-Sakai Akiko, Takata Takanobu, Suzuki Hirokazu, Maruyama Ikuro, Motomiya Yoshihiro, Takeuchi Masayoshi, Scientific Reports, 9:10194, Jul. 2019
  DOI:10.1038/s41598-019-46333-2
• Toxic AGEs (TAGE) theory for pathophysiology of the onset / progression of NAFLD and ALD, Akiko Sakasai-Sakai, Jun-ichi Takano, Atsushi Fukumura, Takanobu Takata, Mikihiro Tsutsumi, Masayoshi Takeuchi, The journal of Japan Mibyo System Association, 24:19-25, Mar. 2018
• Novel biomarker toxic AGEs (TAGE) in the onset / progression of lifestyle-related (LSRD), Takanobu Takata, Akiko Sakasai-Sakai, Masayoshi Takeuchi, The journal of Japan Mibyo System Association, 24:27-33, Aug. 2018
• Effect of Collagen Tripeptide on Atherosclerosis in Healthy Humans, Naohisa Tomosugi, Shoko Yamamoto, Masayoshi Takeuchi, Hideto Yonekura, Yasuhito Ishigaki, Noriaki Numata, Shogo Katsuda, Yasuo Sakai, Journal of Atherosclerosis and Thrombosis, 24:530-538, May 2017
• Diurnal glycemic fluctuation is associated with severity of coronary artery disease in prediabetic patients: Possible role of nitrotyrosine and glyceraldehyde-derived advanced glycation end products., M.Watanabe, Y.Kawai, M.Kitayama, H.Akao, A.Motoyama, M.Wakasa , R.Saito, H.Aoki, K.Fujibayashi, T.Tsuchiya, H.Nakanishi, K.Saito, M.Takeuchi, K.Kajinami, Journal of Cardiology, 69:625-631, Apr. 2017
  DOI:10.1016/j.jjcc.2016.07.001
• Role of Glyceraldehyde-Derived AGEs and Mitochondria in Superoxide Production in Femoral Artery of OLETF Rat and Effects of Pravastatin, (Hori, Eisei);Kikuchi, Chigusa;Nagami, Chie;Kajikuri, Junko;Itoh, Takeo;Takeuchi, Masayoshi;Matsunaga, Tamihide, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40:1903-1908, Nov. 2017
• Ratio of serum levels of AGEs to soluble RAGE is correlated with trimethylamine-N-oxide in non-diabetic subjects, (Tahara, Atsuko);Tahara, Nobuhiro;Yamagishi, Sho-ichi;Honda, Akihiro;Igata, Sachiyo;Nitta, Yoshikazu;Bekki, Munehisa;Nakamura, Tomohisa;Sugiyama, Yoichi;Sun, Jiahui;Takeuchi, Masayoshi;Shimizu, Makiko;Yamazaki, Hiroshi;Fukami, Kei;Fukumoto, Yoshihiro, INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION, 68:1013-1020, Apr. 2017
  DOI:10.1080/09637486.2017.1318117
• High doses of antipsychotic polypharmacy are related to an increase in serum levels of pentosidine in patients with schizophrenia., (Sannohe Takahiro);Ohnuma Tohru;Takeuchi Masayoshi;Tani Eriko;Miki Yasue;Takeda Mayu;Katsuta Narimasa;Takebayashi Yuto;Nakamura Toru;Nishimon Shohei;Kimoto Ayako;Higashiyama Ryoko;Shibata Nobuto;Gohda Tomohito;Suzuki Yusuke;Yamagishi Sho-Ichi;Tomino Yasuhiko;Arai Heii, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 76:42-48, Jun. 2017
  DOI:10.1016/j.pnpbp.2017.02.019
• Glyceraldehyde-Derived Advanced Glycation End Products Accumulate Faster Than N-epsilon-(Carboxymethyl) Lysine, (Yokota, Mami);Sekita, Marie;Okano, Yuri;Masaki, Hitoshi;Takeuchi, Masayoshi;Tokudome, Yoshihiro, ANNALS OF DERMATOLOGY, 29:508-511, Aug. 2017
  DOI:10.5021/ad.2017.29.4.508
• Toxic AGE (TAGE) Theory for the Pathophysiology of the Onset/Progression of NAFLD and ALD, Masayoshi Takeuchi, Jun-ichi Takino, Akiko Sakasai-Sakai, Takanobu Takata, Mikihiro Tsutsumi, Nutrients, 9:634, Jun. 2017
  DOI:10.3390/nu9060634
• Generation of glyceraldehyde-derived advanced glycation end-products in pancreatic cancer cells and the potential of tumor promotion, Takanobu Takata, Tadashi Ueda, Akiko Sakasai-Sakai, Masayoshi Takeuchi, World Journal of Gastroenterology, 23:4910-4919, Jul. 2017
• Gene Expression Changes Associated with the Loss of Heterogeneous Nuclear Ribonucleoprotein M Function, (Jun-ichi Takino), Kentaro Nagamine, Mikoto Suzuki, Akiko Sakasai-Sakai, Masayoshi Takeuchi, Takamitsu Hori, American Journal of Molecular Biology, 7:87-98, Apr. 2017
• Involvement of toxic AGEs(TAGE) in the onset / progrssion of nonalcoholic fatty liver disease (NAFLD): A novel prevention strategy, Masayoshi Takeuchi,Akiko Sakasai-Sakai,Takanobu Takata, 23:20-30, 2017
• Impact of intracellular glyceraldehyde-derived advanced glycation end-products on human hepatocyte cell death, Akiko Sakasai-Sakai,Takanobu Takata,Jun-ichi Takino,Masayoshi Takeuchi, Scientific Reports, 7:14282, Oct. 2017
• Effect of Collagen Tripeptide on Atherosclerosis in Healthy Humans., N.Tomosugi, S.Yamamoto, M.Takeuchi, H.Yonekura, Y.Ishigaki, N.Numata, S.Katsuda, Y.Sakai, Journal of atherosclerosis and thrombosis, 24:530-538, May 2017
• Serum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related Diseases, M.Takeuchi, Diagnostics, 6:1-22, 2016
  DOI:10.3390/diagnostics6020023
• Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial)., (M.Shimomura), J.Oyama, M.Takeuchi, Y.Shibata, Y.Yamamoto, T.Kawasaki, H.Komoda, K.Kodama, M.Sakuma, S.Toyoda, Y.Inoue, Mine Daigo, M.Natsuaki, A.Komatsu, Y.Hikichi, S.Yamagishi, T.Inoue , K.Node, Heart and vessels, 31:1583-1589, 2016
  DOI:10.1007/s00380-015-0773-y
• Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma, (J.Takino), K.Nagamine, T.Hori, A.Sakasai-Sakai, M.Takeuchi, World Journal of Hepatology, 7:2459-2469, Aug. 2015
• Toxic AGEs (TAGE) theory in the pathogenesis of NAFLD and ALD, M.Takeuchi, A.Sakasai-Sakai, J.Takino, T.Takata, T.Ueda, M.Tsutsumi, International Journal of Diabetes and Clinical Researsh, 2:1-5, Jul. 2015
• Usefulness of toxic AGEs (TAGE) as a biomarker for fertility treatment, A.Sakasai-Sakai, M.Jinno, M.Takeuchi, Meeting of the Japan Mibyou System Association, 21:93, Mar. 2015
• Involvement of toxic AGEs(TAGE) in the onset/deterioration of lifestyle-related diseases -New preventive strategy-:-Toxic truth about dietary AGEs and sugars-, M.Takeuchi, J.Takino, A.Sakasai-Sakai, T.Takata, T.Ueda , Journal of Kanazawa Medical University, 40:95-103, 2015
• The association between glyceraldehyde-derived advanced glycation end-products and colorectal cancer risk, (S.Y.Kong), M.Takeuchi, H.Hyogo, G.McKeown-Eyssen, S.Yamagishi, K.Chayama, P.J.O'Brien, P.Ferrari, K.Overvad, A.Olsen, A.Tjonneland, M.Boutron-Ruault, N.Bastide, F.Carbonnel, T.Kuehn, R.Kaaks, H.Boeing, K.Aleksandrova, A.Trichopoulou, P.Lagiou, E.Vasilopoulou, G.Masala, V.Pala, M.D.Magistris, R.Tumino, A.Naccarati, H.B.Bueno-De-Mesquita, P.H.Peeters, E.Weiderpass, J.R.Quiros, P.Jakszyn, M.Sanchez, M.Dorronsoro, D.Gavrila, E.Ardanaz, M.Rutegard, H.Nystroem, N.Wareham, K.Khaw, K.Bradbury, I.Romieu, H.Freisling, F.Stavropoulou, M.J.Gunter, A.J.Cross, E.Riboli, M.Jenab, W.R.Bruce, Cancer Epidemiology Biomarkers & Prevention, 24:1855-1863, 2015
  DOI:10.1158/1055-9965.EPI-15-0422
• Serum levels of toxic AGEs (TAGE) may be a promising novel biomarker in development and progression of NASH., M.Takeuchi, A.Sakasai-Sakai, T.Takata, T.Ueda, J.Takino, M.Tsutsumi, H.Hyogo, S.Yamagishi, Medical Hypotheses, 84:490-493, 2015
• Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function, (M.Kajikawa), A.Nakashima, N.Fujimura, T.Maruhashi, Y.Iwamoto, A.Iwamoto, T.Matsumoto, N.Oda, T.Hidaka, Y.Kihara, K.Chayama, C.Goto, Y.Aibara, K.Noma, M.Takeuchi, T.Matsui, S.Yamagishi, Y.Higashi, Diabetes Care, 38:119-125, 2015
  DOI:10.2337/dc14-1435
• Oral L-Carnitine Supplementation Increases Trimethylamine-N-oxide but Reduces Markers of Vascular Injury in Hemodialysis Patients, (K.Fukami), S.Yamagishi, K.Sakai, Y.Kaida, M.Yokoro, S.Ueda, Y.Wada, M.Takeuchi, M.Shimizu, H.Yamazaki, S.Okuda, Journal of Cardiovascular Pharmacology, 65:289-295, 2015
  DOI:10.1097/FJC.0000000000000197
• In vitro identification of nonalcoholic fatty liver disease-related protein hnRNPM, (J.Takino), K.Nagamine, M.Takeuchi, T.Hori, World Journal of Gastroenterology, 21:1784-1793, 2015
  DOI:10.3748/wjg.v21.i6.1784
• Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells, (Y.Koriyama), A.Furukawa, M.Muramatsu, J.Takino, M.Takeuchi, Scientific Reports, 5:1-7, 2015
  DOI:10.1038/srep13313
• Elevation of serum levels of advanced glycation end products in patients with non-B or non-C hepatocellular carcinoma, (H.Kan), S.Yamagishi, A.Ojima, K.Fukami, S.Ueda, M.Takeuchi, H.Hyogo, H.Akita, K.Chayama, Journal of Clinical Laboratory Analysis, 29:480-484, 2015
  DOI:10.1002/jcla.21797
• Clinical and biochemical factors associated with area and metabolic activity in the visceral and subcutaneous adipose tissues by FDG-PET/CT, (N.Tahara), S.Yamagishi, N.Kodama, A.Tahara, A.Honda, Y.Nitta, S.Igata, T.Matsui, M.Takeuchi, H.Kaida, S.Kurata, T.Abe, Y.Fukumoto, Journal of Clinical Endocrinology & Metabolism, 100:E739-E747, 2015
  DOI:10.1210/jc.2014-3896
• Assessment of total sugar and glucose concentrations in commonly consumed beverages in Japan, M.Takeuchi, J.Takino, H.Shirai, M.Kawakami, S.Furuno, Y.Kobayashi, Nutrition and Food Technology:Open Access, 1:1-9, 2015
• Assessment of the concentrations of various advanced glycation end-products in beverages and foods that are commonly consumed in Japan, M.Takeuchi, J.Takino, S.Furuno, H.Shirai, M.Kawakami, M.Muramatsu, Y.Kobayashi, S.Yamagishi, PLoS One, 10:e0118652-e0118652, 2015
  DOI:10.1371/journal.pone.0118652
• Altered serum glyceraldehyde-derived advanced glycation end product (AGE) and soluble AGE receptor levels indicate carbonyl stress in patients with schizophrenia, (M.Takeda), T.Ohnuma, M.Takeuchi, N.Katsuta, H.Maeshima, Y.Takebayashi, M.Higa, T.Nakamura, S.Nishimon, T.Sannohe, Y.Hotta, R.Hanzawa, R.Higashiyama, N.Shibata, T.Gohda, Y.Suzuki, S.Yamagishi, Y.Tomino, H.Arai, Neuroscience Letters, 593:51-55, 2015
  DOI:10.1016/j.neu1et.2015.03.002
• Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies., M.Takeuchi, J.Takino, A.Sakasai-Sakai, T.Takata, T.Ueda, M.Tsutsumi, H.Hyogo, S.Yamagishi, World journal of hepatology [electronic resource], 6:880-893, Dec. 2014
• Amelioration of experimental autoimmune uveoretinitis by inhibition of glyceraldehyde-derived advanced glycation end-product formation., (Z.Dong), D.Iwata, N.Kitaichi, M.Takeuchi, M.Sato, N.Endo, K.Iwabuchi, R.Ando, J.Fukuhara, S.Kinoshita, A.Lennikov, M.Kitamura, K.Mizuuchi, A.Kanda, K.Noda, K.Namba, S.Yamagishi, S.Ohno, S.Ishida, Journal of leukocyte biology, 96:1077-1085, Dec. 2014
• Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients., (K.Yanagisawa), J.Ashihara, S.Obata, N.Wada, M.Takeuchi, Y.Nishino, S.Maeda, Y.Ishibashi, S.Yamagishi, Diabetes/metabolism research and reviews, 30:693-700, Nov. 2014
  DOI:10.1002/dmrr.2537
• Sulforaphane inhibits advanced glycation end product-induced pericyte damage by reducing expression of receptor for advanced glycation end products., (S.Maeda), T.Matsui, A.Ojima, M.Takeuchi, S.Yamagishi, Nutrition research., 34:807-813, Sep. 2014
  DOI:10.1016/j.nutres.2014.08.010
• Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis., (S.Nakashima), T.Matsui, M.Takeuchi, S.Yamagishi, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 46:717-721, Sep. 2014
• Effect of statins on the serum soluble form of receptor for advanced glycation end-products and its association with coronary atherosclerosis in patients with angina pectoris., (T.Nozue), S.Yamagishi, M.Takeuchi, T.Hirano, S.Yamamoto, S.Tohyama, K.Fukui, S.Umezawa, Y.Onishi, T.Kunishima, K.Hibi, M.Terashima, I.Michishita, IJC metabolic & endocrine., 4:47-52, Jul. 2014
• Advanced glycation end products impair glucose-induced insulin secretion from rat pancreatic β-cells., (H.Hachiya), Y.Miura, K.Inoue, K.H.Park, M.Takeuchi, K.Kubota, Journal of hepato-biliary-pancreatic sciences., 21:134-141, Feb. 2014
• Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report., (I.Nakamura), J.Oyama, H.Komoda, A.Shiraki, Y.Sakamoto, I.Taguchi, A.Hiwatashi, A.Komatsu, M.Takeuchi, S.Yamagishi, T.Inoue, K.Node, Cardiovascular diabetology [electronic resource], 13:15;1-8, Jan. 2014
  DOI:10.1186/1475-2840-13-15
• DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice, Ojima, Ayako;Matsui, Takanori;Maeda, Sayaka;Takeuchi, Masayoshi;Inoue, Hiroyoshi;Higashimoto, Yuichiro;Yamagishi, Sho-ichi, LABORATORY INVESTIGATION, 94:422-429, 2014
  DOI:10.1038/labinvest.2014.5
• Amelioration of experimental autoimmune uveoretinitis by inhibition of glyceraldehyde-derived advanced glycation end-product formation, Dong, Zhenyu;Iwata, Daiju;Kitaichi, Nobuyoshi;Takeuchi, Masayoshi;Sato, Masashi;Endo, Noriko;Iwabuchi, Kazuya;Ando, Ryo;Fukuhara, Junichi;Kinoshita, Satoshi;Lennikov, Anton;Kitamura, Mizuki;Mizuuchi, Kazuomi;Kanda, Atsuhiro;Noda, Kousuke;Namba, Kenichi;Yamagishi, Sho-Ichi;Ohno, Shigeaki;Ishida, Susumu, JOURNAL OF LEUKOCYTE BIOLOGY, 96:1077-1085, 2014
  DOI:10.1189/jlb.3A0513-288RRR
• Advanced glycation end products impair glucose-induced insulin secretion from rat pancreatic -cells, Hachiya, Hiroyuki;Miura, Yoshikazu;Inoue, Ken-ichi;Park, Kyung Hwa;Takeuchi, Masayoshi;Kubota, Keiichi, JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 21:134-141, 2014
  DOI:10.1002/jhbp.12
• Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product(AGE) - receptor for AGE(RAGE) axis, and albuminuria in Japanese type 2 diabetes., (K.Sakata), M.Hayakawa, Y.Yano, N.Tamaki, N.Yokota, T.Eto, R.Watanabe, N.Hirayama, T.Matsuo, K.Kuroki, S.Sagara, O.Mishima, M.Koga, N.Nagata, Y.Nishino, K.Kitamura, K.Kario, M.Takeuchi, S.Yamagishi, Diabetes/metabolism research and reviews, 29:624-630, Nov. 2013
• Blockade by phosphorothioate aptamers of advanced glycation end products-induced damage in cultured pericytes and endothelial cells., (Y.Higashimoto), T.Matsui, Y.Nishino, J.Taira, H.Inoue, M.Takeuchi, S.Yamagishi, Microvascular research, 90:64-70, Nov. 2013
• Presence of glyceraldehyde-derived advanced glycation end-products in the liver of insulin-resistant mice, (Y.Ebata), J.Takino, H.Tsuchiya, T.Sakabe, Y.Ikeda, S.Hama, K.Kogure, M.Takeuchi, G.Shiota, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition., 83:137-141, Sep. 2013
• Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction., (R.Ando), S.Ueda, S.Yamagishi, H.Miyazaki, Y.Kaida, K.Kaifu, M.Yokoro, Y.Nakayama, N.Obara, K.Fukami, M.Takeuchi, S.Okuda, Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease., 10:436-441, Sep. 2013
• DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy, Higashimoto, Yuichiro;Kaida, Yusuke;Matsui, Takanori;Fukami, Kei;Okuda, Seiya;Yamagishi, Sho-ichi;Takeuchi, Masayoshi;Inoue, Hiroyoshi, JOURNAL OF PHARMACOLOGICAL SCIENCES, 124:225P-225P, Sep. 2013
• DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy, (Y.Kaida), K.Fukami, T.Matsui, Y.Higashimoto, Y.Nishino, N.Obara, Y.Nakayama, R.Ando, M.Toyonaga, S.Ueda, M.Takeuchi, H.Inoue, S.Okuda, S.Yamagishi, Diabetes., 62:3241-3250, Sep. 2013
• Asymmetrical dimethylarginine level is independently associated with circulating levels of RAGE and PEDF, (N.Tahara), S.Yamagishi, A.Tahara, M.Takeuchi, T.Imaizumi, International journal of cardiology, 167:3072-3074, Sep. 2013
• Telmisartan inhibits AGE-induced podocyte damage and detachment., (K.Fukami), S.Yamagishi, K.Kaifu, T.Matsui, Y.Kaida, S.Ueda, M.Takaeuchi, K.Asanuma, S.Okuda, Microvascular research, 88:79-83, Jul. 2013
• Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis., (S.Maeda), T.Matsui, M.Takeuchi, S.Yamagishi, Diabetes/metabolism research and reviews, 29:406-412, Jul. 2013
• Acetaldehyde-derived advanced glycation end-products promote alcoholic liver disease., N.Hayashi, J.George, M.Takeuchi, A.Fukumura, N.Toshikuni, T.Arisawa, M.Tsutsumi, PloS one, 8:e70034;1-14, Jul. 2013
• Serum levels of advanced glycation end-products (AGEs) in dialysis patients -Effects of low-dose sevelamer hydrochloride-, (H.Muramoto), H.Mutoh, M.Takeuchi, 46:467-473, May 2013
• Nighttime blood pressure, nighttime glucose values, and target-organ damages in treated type 2 diabetes patients., (Y.Yano), M.Hayakawa, K.Kuroki, H.Ueno, S.Yamagishi, M.Takeuchi, T.Eto, N.Nagata, M.Nakazato, K.Shimada, K.Kario, Atherosclerosis., 227:135-139, Mar. 2013
• Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: The JAPAN-ACS sub-study., (Y.Fukushima), H.Daida, T.Morimoto, T.Kasai, K.Miyauchi, S.Yamagishi, M.Takeuchi, T.Hiro, T.Kimura, Y.Nakagawa, M.Yamagishi, Y.Ozaki, M.Matsuzaki, Cardiovascular diabetology [electronic resource], 0.503472222, Jan. 2013
• PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation., (Y.Ishibashi), T.Matsui, K.Ohta, R.Tanoue, M.Takeuchi, K.Asanuma, K.Fukami, S.Okuda, K.Nakamura, S.Yamagishi, Microvascular research, 85:54-58, Jan. 2013
• Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression., (A.Ojima), Y.Ishibashi, T.Matsui, S.Maeda, Y.Nishino, M.Takeuchi, K.Fukami, S.Yamagishi, The American journal of pathology., 182:132-141, Jan. 2013
• Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans., (N.Tahara), S.Yamagishi, M.Takeuchi, A.Tahara, K.Kaifu, S.Ueda, S.Okuda, T.Imaizumi, Clinical biochemistry, 46:300-303, Dec. 2012
• Positive association between serum level of glyceraldehyde-derived advanced glycation end products (AGEs) and vascular inflammation evaluated by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)., (N.Tahara), S.Yamagishi, M.Takeuchi, A.Honda, A.Tahara, Y.Nitta, N.Kodama, M.Mizoguchi, H.Kaida, M.Ishibashi, N.Hayabuchi, T.Matshui, T.Imaizumi, Diabetes Care., 35:2618-2625, Dec. 2012
• Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase., (Y.Ishibashi), T.Matsui, M.Takeuchi, S.Yamagishi, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 45:387-390, Dec. 2012
• Serum levels of pigment epithelium-derived factor, a novel marker of insulin resistance, are independently associated with fasting apolipoprotein B48 levels in humans, (N.Tahara), S.Yamagishi, A.Tahara, M.Takeuchi, T.Imaizumi, Clinical biochemistry, 45:1404-1408, Nov. 2012
• Metoformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression., (Y.Ishibashi), T.Matsui, M.Takeuchi, S.Yamagishi, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 44:891-895, Nov. 2012
• Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level., (Y.Ishibashi), S.Yamagishi, T.Matsui, K.Ohta, R.Tanoue, M.Takeuchi, S.Ueda, K.Nakamura, S.Okuda, Metabolism: clinical and experimental, 61:1067-1072, Aug. 2012
• Adiponectin is inversely associated with ratio of serum levels of AGEs to sRAGE and vascular inflammation., (N.Tahara), S.Yamagishi, A.Tahara, M.Ishibashi, N.Hayabuchi, M.Takeuchi, T.Imaizumi, International journal of cardiology, 158:461-462, Jul. 2012
• Glucose-dependent insulinotropic polypeptide (GIP) inhibits signaling pathways of advanced glycation end products (AGEs) in endothelial cells via its anti-oxidative properties., (A.Ojima), T.Matsui, S.Maeda, M.Takeuchi, S.Yamagishi, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 44:501-505, Jun. 2012
• Glycer-AGEs-RAGE signaling enhances the angiogenic potential of HCC by upregulating VEGF expression., (J.Takino), S.Yamagishi, M.Takeuchi, World journal of gastroenterology : WJG., 18:1781-1788, Apr. 2012
• Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGE-induced proximal tubular cell injury., (Y.Ishibashi), T.Matsui, M.Takeuchi, S.Yamagishi, Pharmacological research : the official journal of the Italian Pharmacological Society., 65:297-302, Mar. 2012
• AGEs and Liver Disease, Anti-Aging Medicine, 8:55-61, Feb. 2012
• Pigment epithelium-derived factor (PEDF) blocks advanced glycation end products (AGEs)- RAGE-induced suppression of adiponectin mRNA level in adipocytes by inhibiting NADPH oxidase- mediated oxidative stress generation, (S.Maeda), T.Matsui, M.Takeuchi, S.Yamagishi, International journal of cardiology, 152:408-410, Nov. 2011
• Sitagliptin augments suppressive effects of GLP-1 on advanced glycation end product (AGE)-receptor axis in endothelial cells, (Y.Ishibashi), T.Matsui, M.Takeuchi, S.Yamagishi, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 43:731-734, Sep. 2011
• Glucagon-like peptide-1 suppresses advanced glycation end product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing AGE receptor level, (Y.Ishibashi), Y.Nishino, T.Matsui, M.Takeuchi, S.Yamagishi, Metabolism: clinical and experimental, 60:1271-1277, Sep. 2011
• Rosuvastatin blocks advanced glycation end products-elicited reduction of macrophage cholesterol efflux by suppressing NADPH oxidase activity via inhibition of geranylgeranylation of Rac-1, (Y.Ishibashi), T.Matsui, M.Takeuchi, S.Yamagishi, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 43: 619-624, Aug. 2011
• Activation of receptor for advanced glycation end products induces osteogenic differentiation of vascular smooth muscle cells., (T.Suga), T.Iso, T.Shimizu, T.Tanaka, S.Yamagishi, M.Takeuchi, T.Imaizumi, M.Kurabayashi, Journal of atherosclerosis and thrombosis., 18:670-683, Aug. 2011
• Vardenafil, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP., (Y.shibashi), T.Matsui, M.Takeuchi, S.Yamagishi, Clinical and experimental medicine, 11:131-135, Jun. 2011
• Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease, (T.Nakamura), E.Sato, N.Fujuwara, Y.Kawagoe, H.Koide, Y.Ueda, M.Takeuchi, S.Yamagishi, Clinical cardiology., 34:372-377, Jun. 2011
• Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis, (T.Matsui), Y.Nishino, M.Takeuchi, S.Yamagishi, Pharmacological research : the official journal of the Italian Pharmacological Society., 63:383-388, Mar. 2011
• Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis., (Maeda S), Matsui T, Takeuchi M, Yoshida Y, Yamakawa R, Fukami K, Yamagishi S, Pharmacological research : the official journal of the Italian Pharmacological Society., 63: 241-248, Mar. 2011
• Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells, (T.Matsui), Y.Nishino, S.Maeda, M.Takeuchi, S.Yamagishi, Microvascular research, 81:269-273, Mar. 2011
• Combination therapy with nateglinide and telmisartan ameliorates insulin resistance in Zucker fatty rats by suppressing advanced glycation end product receptor axis., (Miura K), Kitahara Y, Kajioka T, Takeuchi M, Yamagishi S, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 43: 226-228, Mar. 2011
• Advanced glycation end-products accumulation compromises embryonic development and achievement of pregnancy by assisted reproductive technology., (Jinno M), Takeuchi M, Watanabe A, Teruya K, Hirohama J, Eguchi N, Miyazaki A, Human reproduction (Oxford, England), 26: 604-610, Mar. 2011
• Co-treatement with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs)-elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property., (Maeda S), Matsui T, Takeuchi M, Yamagishi S, International journal of cardiology, 146: 264-266, Feb. 2011
• Involvement of aldosterone-mineralcorticoid receptor system in advanced glycation end product (AGE)- elicited plasminogen activator inhibitor-1 (PAI-1) expression in diabetes., (Matsui T), Takeuchi M, Yamagishi S, International journal of cardiology, 145: 566-567, Dec. 2010
• MK615 decreases RAGE expression and inhibits TAGE-induced proliferation in hepatocellular carcinoma cells., (Sakuraoka Y), Sawada T, Okada T, Shiraki T, Miura Y, Hiraishi K, Osawa T, Adaci M, Takino J, Takeuchi M, Kubota K, World journal of gastroenterology : WJG., 16: 5334-5341, Nov. 2010
• Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: A novel therapeutic strategy., Takeuchi M, Takino J, Yamagishi S, Current drug targets, 11: 1468-1482, Nov. 2010
• Pigment epithelium-derived factor (PEDF) inhibits diabetes- or advanced glycation end product (AGE)- induced platelet CD40 ligand overexpression in rats., (Yamagishi S), Matsui T, Ueda S, Takeuchi M, International journal of cardiology, 144: 283-285, Oct. 2010
• Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin, (Unoki-Kubota H), Yamagishi S, Takeuchi M, Bujo H, Saito Y, Protein and peptide letters, 17: 1177-1181, Sep. 2010
• Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation., (Ide Y), Matsui T, Ishibashi Y, Takeuchi M, Yamagishi S, Microvascular research, 80: 227-232, Sep. 2010
• Atorvastain reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs)., (Nakamura T), Sato E, Fujiwara N, Nawagoe Y, Takeuchi M, Maeda S, Yamagishi S, Oxidative medicine and cellular longevity, 3: 304-307, Sep. 2010
• Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-, (Matsui T), Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S, Biochemical and biophysical research communications, 398: 326-330, Jul. 2010
• Insulin resistence is an independent correlate of high serum levels of advanced glycation end products (AGEs) and low testosterone in non-diabetic men., (Tahara N), Imaizumi T, Takeuchi M, Yamagishi S, Oxidative medicine and cellular longevity, 3: 262-265, Jul. 2010
• Immunological detection of fructose-derived advanced glycation end-products., Takeuchi M, Iwaki M, Takino J, Shirai H, Kawakami M, Bucala R, Yamagishi S, Laboratory investigation; a journal of technical methods and pathology., 90: 1117-1127, Jul. 2010
• Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH., (Kimura Y), Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K, Journal of gastroenterology., 45: 750-757, Jul. 2010
• Involvement of TAGE-RAGE system in the pathogenesis of diabetic retinopathy., Takeuchi M, Takino J, Yamagishi S, Journal of ophthalmology, 2010: 170393, Jun. 2010
• Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products., (Takino J), Yamagishi S, Takeuchi M, Journal of oncology., 2010: 739852, Jun. 2010
• An α-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes., (Tsunosue M), Mashiko N, Ohta Y, Matsuo Y, Ueda K, Ninomiya M, Tanaka S, Hoshiko M, Yoshiyama Y, Takeuchi M, Ueda S, Yamagishi S, Clinical and experimental medicine, 10: 139-141, Jun. 2010
• Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced, (Matsui T), Takeuchi M, Yamagishi S, Biochemical and biophysical research communications, 396: 566-570, May 2010
• Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population., (Yamagishi S), Matsui T, Adachi H, Takeuchi M, Pharmacological research : the official journal of the Italian Pharmacological Society., 61: 103-107, Feb. 2010
• The formation of intracellular glyceraldehyde-derived advanced glycation end-products and cytotoxicity., (Takino J), Kobayashi Y, Takeuchi M, Journal of gastroenterology., 45: 646-655, Jan. 2010
• Neuropathy induced by exogenously administered advanced glycation end-products in rats., (Nishizawa Y), Wada R, Baba M, Takeuchi M, Hanyu-Ishibashi C, Yagihashi S, Journal of diabetes investigation, 1: 40-49, Jan. 2010
• Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression., (Matsui T), Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S, Pharmacological research : the official journal of the Italian Pharmacological Society., 61: 34-39, Jan. 2010
• Glucagon-like peptide-1 (GLP-1) inihibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression., (Ishibashi Y), Matsui T, Takeuchi M, Yamagishi S, Biochemical and biophysical research communications, 391: 1405-1408, Jan. 2010
• Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock, (Nakamura T), Sato E, Fujiwara N, Kawagoe W, Suzuki T, Ueda Y, Yamada S, Shoji H, Takeuchi M, Ueda S, Matsui T, Adachi H, Okuda S, Yamagishi S, Pharmacological research : the official journal of the Italian Pharmacological Society., 60: 515-518, Dec. 2009
• Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients, (Nakamura T), Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, Yamada Y, Takeuchi M, Fukami K, Ueda S, Adachi H, Matsui T, Okuda S, Yamagishi S, Metabolism: clinical and experimental, 58: 1624-1628, Nov. 2009
• Low-density lipoprotein levels are one of the independent determinants of circulating levels of advanced glycation end products in nondiabetic subjects, (Yamagishi S), Adachi H, Matsui T, Nakamura K, Takeuchi M, Enomoto M, Fukami A, Otsuka M, Kumagae S, Nanjo Y, ueda S, Imaizumi T, Clinical cardiology., 32: E12-E15, Sep. 2009
• Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer’s disease., Takeuchi M, Yamagishi S, Journal of Alzheimer's disease : JAD, 16: 845-858, Aug. 2009
• Up-regulation in receptor for advanced glycation end-products in inflammatory circumstances in bovine coccygeal intervertebral disc specimens in vitro, (Yoshida T), Park JS, Yokosuka K, Jinbo K, Yamada K, Sato K, Takeuchi M, Yamagishi S, Nagata K, Spine, 34: 1544-1548, Jul. 2009
• Nifedipine, a calcium channel blocker, inhibits advanced glycation end products (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammma activation, (Matsui T), Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S, Biochemical and biophysical research communications, 385: 269-272, Jul. 2009
• Pigment epithelium-derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs), (Yamagishi S), Matsui T, Takenaka K, Nakamura K, Takeuchi M, Inoue H, Diabetes/metabolism research and reviews, 25: 266-271, Mar. 2009
• Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients, (Nakamura K), Adachi H, Matsui T, Kurita Y, Takeuchi M, Yamagishi S, Metabolism: clinical and experimental, 58: 421-425, Mar. 2009
• Effects of high-AGE beverage on RAGE and VEGF expressions in the liver and kidneys, (Sato T), Wu X, Shimogaito N, Takino J, Yamagishi S, Takeuchi M, European journal of nutrition, 48: 6-11, Feb. 2009
• Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-defient mice, (You K), Hirayama A, Ishizaki K, Yamada A, Takeuchi M, Yamagishi S, Morito N, Nakano T, Ojima M, Shimokata H, Itoh K, Takahashi S, Yamamoto M, Genes to cells : devoted to molecular & cellular mechanisms, 13: 1159-1170, Nov. 2008
• Possible involvement of advanced glycation end products (AGEs) in the pathogenesis of Alzheimer’s disease, Takeuchi M, Yamagishi S, Current pharmaceutical design, 14: 973-978, Oct. 2008
• Pigment epithelium-derived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation, (Yoshida T), Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, koga H, Ueno T, Sata M, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 40: 620-625, Sep. 2008
• Glyceraldehyde-derived advanced glycation end products (AGEs): A novel biomarker of postprandial hyperglycemia in diabetic rats, (Kitahara Y), Takeuchi M, Miura K, Mine T, Matsui T, Yamagishi S, Clinical and experimental medicine, 8: 175-177, Sep. 2008
• Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferators-activated receptor-gamma activation, (Yamagishi S), Matsui T, Nakamura K, Takeuchi M, Inoue H, Protein and peptide letters, 15: 850-853, Aug. 2008
• Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes, (Nakamura K), Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T, Microvascular research, 76: 52-56, May 2008
• Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells, (Iwamoto K), Kanno K, Hyogo H, Yamagishi S, Takeuchi M, Tazuma S, Chayama K, Journal of gastroenterology., 43: 298-304, Apr. 2008
• Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation, (Yoshida T), Yamagishi S, Matsui T, Nakamura K, Ueno T, Takeuchi M, Sata M, The Journal of international medical research., 36: 237-243, Mar. 2008
• Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes., (Nakamura K), Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T, Diabetes/metabolism research and reviews, 24: 109-114, Feb. 2008
• Telmisartan blocks advanced glycation end product (AGE)-induced plasminogen activator inhibitor-1 (PAI-1) gene expression in endothelial cells via activation of peroxisome proliferator-activated receptor-γ (PPAR-γ), (Matsui T), Nakamura K, Takeuchi M, Yamagishi S, Letters in drug design & discovery, 5: 477-480, Jan. 2008
• Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species, (Yamagishi S), Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Okuda S, Imaizumi T, Ophthalmic research., 40: 10-15, Jan. 2008
• Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression, (Yamagishi S), Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Fukami K, Okuda S, Imaizumi T, Microvascular research, 75: 130-134, Jan. 2008
• Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects, (Nakamura K), Yamagishi S, Matsui T, Adachi H, Takeuchi M, Imaizumi T, Clinical and experimental medicine, 7: 188-190, Dec. 2007
• Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population, (Yamagishi S), Adachi H, Takeuchi M, Enomoto M, Fukami K, Matsui T, Nakamura K, Imaizumi T, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 39: 845-848, Nov. 2007
• Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxidase synthase (eNOS) reduction through its anti-oxidative properties, (Yamagishi S), Ueda S, Matsui T, Nakamura K, Imaizumi T, Takeuchi M, Okuda S, Protein and peptide letters, 14: 832-835, Aug. 2007
• Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through down-regulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation, (Matsui T), Yamagishi S, Ueda S, Nakamura K, Imaizumi T, Takeuchi M, Inoue H, The Journal of international medical research., 35: 482-489, Jul. 2007
• In vitro selection of DNA aptamers that block toxic effects of AGE on cultured retinal pericytes, (Higashimoto Y), Yamagishi S, Nakamura K, Matsui T, Takeuchi M, Noguchi M, Inoue H, Microvascular research, 74: 65-69, Jul. 2007
• Elevated levels of serum advanced glycation end-products in patients with nonalcoholic steatohepatitis, (Hyogo H), Yamagishi S, Iwamoto K, Arihiro K, Takeuchi M, Sato T, Ochi H, Nakano M, Nabeshima Y, Inoue M, Ishitobi T, Chayama K, Tazuma S, Journal of gastroenterology and hepatology., 22: 1112-1119, Jul. 2007
• Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells, (Yamamoto Y), Yonekura H, Watanabe T, Sakurai S, Li H, Harashima A, Myint KM, Osawa M, Takeuchi A, Takeuchi M, Yamamoto H, Diabetes research and clinical practice., 77 Suppl 1: S30-S40, Jun. 2007
• Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer’s disease, Takeuchi M, Sato T, Takino J, Kobayashi Y, Furuno S, Kikuchi S, Yamagishi S, Medical hypotheses, 69: 1358-1366, Jun. 2007
• Immunohistochemical demonstration of advanced glycation end products and the effects of advanced glycation end products in ossified ligament tissues in vitro., (Yokosuka K), Park JS, Jimbo K, Yoshida T, Yamada K, Sato K, Takeuchi M, Yamagishi S, Nagata K, Spine, 32: E337-E339, May 2007
• Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes, (Unoki H), Bujo H, Yamagishi S, Takeuchi M, Imaizumi T, Saito Y, Diabetes research and clinical practice., 76: 236-244, May 2007
• Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation, (Yokoi M), Yamagishi S, Takeuchi M, Matsui T, Yoshida Y, Ohgami K, Amano-Okamoto T, Ohno S, The British journal of ophthalmology., 91: 397-398, Mar. 2007
• Pigment epithelium-derived factor (PEDF) blocks advanced glycation end product (AGE)-induced angiogenesis in vitro., (Yamagishi S), Nakamura K, Matsui T, Yoshida T, Takeuchi M, Imaizumi T, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 39: 233-235, Mar. 2007
• Oral administration of AST-120 (Kremezine) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders, (Yamagishi S), Nakamura K, Matsui T, Inoue H, Takeuchi M, Medical hypotheses, 69: 666-668, Mar. 2007
• Pigment epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats, (Yamagishi S), Matsui T, Nakamura K, Yoshida T, Takeuchi M, Inoue H, Yoshida Y, Imaizumi T, Ophthalmic research., 39: 92-97, Feb. 2007
• Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells, (Matsui T), Yamagishi S, Nakamura K, Inoue H, Takeuchi M, The Journal of international medical research., 35: 107-112, Feb. 2007
• Atorvastatin inhibits advanced glycation end products (AGE)-induced C-reactive expression in hepatoma cells by suppressing reactive oxygen species generation, (Yoshida T), Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Makino T, Shimuzu T, Sata M, Vascular disease prevention, 4: 213-216, Feb. 2007
• Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes, (Jinnouchi Y), Yamagishi S, Takeuchi M, Ishida S, Jinnouchi Y, Jinnouchi J, Imaizumi T, Clinical and experimental medicine, 6: 191-193, Dec. 2006
• Advanced glycation end-products downregulate intervertebral disc cell production of proteoglycans in vitro, (Yokosuka K), Park JS, Jimbo K, Yamada K, Sato K, Tsuru M, Takeuchi M, Yamagishi S, Nagata K, Journal of neurosurgery. Spine, 5: 324-329, Oct. 2006
• Susceptibility of brain microvascular endothelial cells to advanced glycation end products-induced tissue factor upregulation is associated with intracellular reactive oxygen species, (Niiya Y), Abumiya T, Shichinohe H, Kuroda S, Kikuchi S, Ieko M, Yamagishi S, Takeuchi M, Sato T, Iwasaki Y, Brain research., 1108: 179-187, Sep. 2006
• RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low molecular weight heparin, (Myint KM), Yamamoto Y, Doi T, Kato I, Harashima A, Yonekura H, Watanabe T, Shinohara H, Takeuchi M, Tsuneyama K, Hashimoto N, Asano M, Takasawa S, Okamoto H, Yamamoto H, Diabetes., 55: 2510-2522, Sep. 2006
• Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects, (Yamagishi S), Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K, Takeuchi M, Enomoto M, Furuki K, Hino A, Shigeto Y, Imaizumi T, Metabolism: clinical and experimental, 55: 1227-1231, Sep. 2006
• Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation., (Yoshida T), Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Koga H, Ueno T, Sata M, Diabetologia, 49: 3094-3099, Sep. 2006
• Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation., (Yoshida T), Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Ueda T, Sata M, FEBS letters, 580: 2788-2796, Sep. 2006
• Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes, (Shoji T), Koyama H, Morikawa T, Tanaka S, Kizu A, Motoyama K, Mori K, Fukumoto S, Shioi A, Shimogaito N, Takeuchi M, Yamamoto Y, Yonekura H, Yamamoto H, Nishizawa Y, Diabetes., 55: 2245-2255, Aug. 2006
• Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure, (Ueda S), Yamagishi S, Takeuchi M, Kohno K, Shibata R, Matsumoto Y, Kaneyuki U, Fujimura T, Hayashida A, Okuda S, Molecular medicine (Cambridge, Mass.), 12: 180-184, Aug. 2006
• Toxic advanced glycation end product (TAGE) theory in Alzheimer’s disease, (Sato T), Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi M, American journal of Alzheimer's disease and other dementias, 21: 197-208, Jul. 2006
• Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans, (Enomoto M), Adachi H, Yamagishi S, Takeuchi M, Furuki K, Hino A, Hiratsuka A, Takajo Y, Imaizumi T, Metabolism: clinical and experimental, 55: 912-917, Jul. 2006
• Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis, (Yamagishi S), Matsui T, Nakamura K, Takeuchi M, Imaizumi T, Microvascular research, 72: 86-90, Jul. 2006
• TAGE (toxic AGEs) theory in diabetic complications, (Sato T), Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M, Current molecular medicine, 6: 351-358, May 2006
• Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy., (Yamagishi S), Nakamura K, Matsui T, Sato T, Takeuchi M, Medical hypotheses, 66:1019-1021, May 2006
• Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression, (Yamagishi S), Nakamura K, Matsui T, Inagaki Y, Takenaka K, Jinnouchi Y, Yoshida Y, Matsuura T, Narama I, Motomiya Y, Takeuchi M, Inoue H, Yoshimura A, Bucala R, Imaizumi T, The Journal of biological chemistry., 281: 20213-20220, May 2006
• Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell proliferation by suppressing autocrine production of interleukin-2, (Yamagishi S), Kikuchi S, Nakamura K, Matsui T, Takeuchi M, Inoue H, Medicinal chemistry (Sh？riqah (United Arab Emirates)), 2: 265-269, May 2006
• Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver., (Yamagishi S), Nakamura K, Matsui K, Sato T, Takeuchi M, Medical hypotheses, 66:844-846, Apr. 2006
• Protective role of pravastatin in the pathogenesis of the metabolic syndrome., (Yamagishi S), Matsui T, Sato T, Takeuchi M, Medical hypotheses, 66:609-611, Mar. 2006
• Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy., (Yamagishi S), Nakamura K, Matsui T, Takeuchi M, Medical hypotheses, 66:273-275, Feb. 2006
• Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhension molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation, (Yamagishi S), Matsui T, Nakamura T, Takeuchi M, International journal of tissue reactions, 27: 189-195, Dec. 2005
• Cytotoxicity of acetaldehyde-derived advanced glycation end-products (AA-AGE) in alcoholic-induced neuronal degeneration, Takeuchi M, Saito T, Alcoholism, clinical and experimental research., 29 (12 Suppl): 220S-224S, Dec. 2005
• Decerase in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease, (Kitamura M), Kitaichi N, Takeuchi M, Kitamei H, Namba K, Yamagishi S, Iwabuchi K, Onoe K, Ohno S, The British journal of ophthalmology., 89: 1407-1409, Nov. 2005
• Blockade by nifedipine of advanced glycation end product-induced CD40-CD40 ligand interaction in endothelial cells, (Yamagishi S), kikuchi S, Takenaka K, Takeuchi M, Drugs under experimental and clinical research, 31: 221-226, Nov. 2005
• Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (AGE)-injected rats, (Yamagishi S), Takeuchi M, Inoue H, International journal of tissue reactions, 27: 137-143, Sep. 2005
• Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression, (Yamagishi S), Takeuchi M, Matsui T, Nakamura K, Imaizumi T, Inoue H, FEBS letters, 579: 4265-4270, Aug. 2005
• Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (AGE)-injected rats, (Yamagishi S), Takeuchi M, Inoue H, Drugs under experimental and clinical research, 31: 45-51, Jun. 2005
• Met72Thr polymorphism of pigment epithelium-derived factor (PEDF) gene and susceptibility to age-related macular degeneration., (Yamagishi S), Nakamura K, Inoue H, Takeuchi M, Medical hypotheses, 64:1202-1204, Jun. 2005
• Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy, (Yokoi M), Yamagishi S, Takeuchi M, Ohgami K, Okamoto T, Saito W, Muramatsu M, Imaizumi T, Ohno S, The British journal of ophthalmology., 89: 673-675, Jun. 2005
• Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders, (Yamagishi S), Nakamura K, Takeuchi M, Medical hypotheses, 65: 392-394, Apr. 2005
• Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer’s disease, (Yamagishi S), Nakamura K, Inoue H, Kikuchi S, Takeuchi M, Medical hypotheses, 64: 1205-1207, Mar. 2005
• Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients, (Yamagishi S), Nakamura K, Inoue H, Kikuchi S, Takeuchi M, Medical hypotheses, 64: 1208-1210, Mar. 2005
• Nifedipine inhibits tumor necrosis factor-alpha-induced upregulation of monocyte chemoattractant protein-1 mRNA levels by suppressing CD40 expression in endothelial cells, (Yamagishi S), Takeuchi M, Drugs under experimental and clinical research, 31: 13-17, Feb. 2005
• Atheroprotective properties of nifedipine., (Yamagishi S), Takeuchi M, International journal of tissue reactions, 27:63-67, Feb. 2005
• Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property, (Yamagishi S), Takeuchi M, Medical hypotheses, 64: 476-478, Jan. 2005
• Pigment epithelium-derived factor (PEDF) inhibits oxidative stress-induced apoptosis and dysfunction of cultured retinal pericytes, (Amano S), Yamagishi S, Inagaki Y, Nakamura K, Takeuchi M, Inoue H, Imaizumi T, Microvascular research, 69: 45-55, Jan. 2005
• Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrom, (Yamagishi S), Nakamura K, Takeuchi M, Medical hypotheses, 65: 152-154, Jan. 2005
• Receptor for advanced glycation end products is a promising target of diabetic nephropathy, (Yamamoto Y), Doi T, Kato I, Shinohara H, Sakurai S, Yonekura H, Watanabe T, Myint KM, Harashima A, Takeuchi M, Takasawa S, Okamoto H, Hashimoto N, Asano M, Yamamoto H, Annals of the New York Academy of Sciences., 1043: 562-566, 2005
• Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling, (Yamagishi S), Abe R, Inagaki Y, Nakamura K, Sugawara H, Inokuma D, Nakamura H, Shimizu T, Takeuchi M, Yoshimura A, Bucala R, Shimizu H, Imaizumi T, The American journal of pathology., 165: 1865-1874, Dec. 2004
• AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction, (Fukami K), Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M, Motomiya Y, Bucala R, Iida S, Tamaki K, Imaizumi T, Cooper ME, Okuda S, Kidney international., 66: 2137-2147, Dec. 2004
• Glyceraldehyde-derived advanced glycation end products in Alzheimer’s disease, (Choei H), Sasaki N, Takeuchi M, Yoshida T, Ukai W, Yamagishi S, kikuchi S, Saito T, Acta neuropathologica., 108: 189-193, Sep. 2004
• Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells, (Sekido H), Suzuki T, Jomori T, Takeuchi M, Yabe-Nishimura C, Yagihashi S, Biochemical and biophysical research communications, 320: 241-248, Jul. 2004
• Advanced glycation end products increase collagen-specific chaperone protein in mouse diabetic nephropathy, (Ohashi S), Abe H, Takahashi T, Yamamoto Y, Takeuchi M, Arai H, Nagata K, Kita T, Okamoto H, Yamamoto H, Doi T, The Journal of biological chemistry., 279: 19816-19823, May 2004
• Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in viv, (Abe R), Shimizu T, Yamagishi S, Shibaki A, Amano S, Inagaki Y, Watanabe H, Sugawara H, Nakamura H, Takeuchi M, Imaizumi T, Shimizu H, The American journal of pathology., 164: 1225-1232, Apr. 2004
• Nifedipine inhibits tumor necrosis factor-alpha-induced leukocyte adhesion to endothelial cells by suppressing vascular cell adhesion molecule-1 (VCAM-1) expression, (Yamagishi S), Takeuchi M, Drugs under experimental and clinical research, 30: 163-168, Apr. 2004
• Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation, (Yamagishi S), Takeuchi M, Drugs under experimental and clinical research, 30: 169-175, Apr. 2004
• TAGE (toxic AGEs) hypothesis in various chronic diseases, Takeuchi M, Yamagishi S, Medical hypotheses, 63: 449-452, Mar. 2004
• Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo, Takeuchi M, Yamagishi S, Medical hypotheses, 63: 453-455, Mar. 2004
• Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions, (Abe R), Shimizu T, Sugawara H, Watanabe H, Nakamura H, Choei H, Sasaki N, Yamagishi S, Takeuchi M, Shimizu H, The Journal of investigative dermatology, 122: 461-467, Feb. 2004
• Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention, (Yamagishi S), Nakamura K, Takeuchi M, Imaizumi T, International journal of clinical pharmacology research, 24: 129-134, Feb. 2004
• Involvement of advanced glycation end-products (AGEs) in Alzheimer’s disease, Takeuchi M, Kikuchi S, Sasaki N, Suzuki T, Watai T, Iwaki M, Bucala R, Yamagishi S, Current Alzheimer research, 1: 39-46, Feb. 2004
• Advanced glycation end product (AGE) inhibitors and their therapeutic implications in disease, Takeuchi M, Yamagishi S, Iwaki M, Inagaki Y, Nakamura K, Imaizumi T, International journal of clinical pharmacology research, 24: 95-101, Feb. 2004
• Is pigment epithelium-derived factor level in cerebrospinal fluid a promising biomarker for early diagnosis of Alzheimer’s disease?, (Yamagishi S), Inagaki Y, Takeuchi M, Sasaki N, Medical hypotheses, 63:115-117, Jan. 2004
• Inhibition of protein kinase C might be harmful to diabetic retinopathy., (Yamagishi S), Takeuchi M, Medical hypotheses, 63:135-137, Jan. 2004
• AGE down-regulation of monocyte RAGE expression and its association with diabetic complications in type 1 diabetes, (Miura J), Ychigata Y, Yamamoto Y, Takeuchi M, Sakurai S, Watanabe T, Yonekura H, Yamagishi S, Makita Z, Sato A, Omori Y, Yamamoto H, Iwamoto Y, Journal of diabetes and its complications., 18: 53-59, Jan. 2004
• Neurotoxicity of acetaldehyde-derived advanced glycation end products for cultured cortical neurons, Takeuchi M, Watai T, Sasaki N, Choei H, Iwaki M, Ashizawa T, Inagaki Y, Yamagishi S, kikuchi S, Riederer P, Saitop T, Bucala R, Kameda Y, Journal of neuropathology and experimental neurology., 62: 486-496, May 2003
• Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy, (Yamagishi S), Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T, International journal of clinical pharmacology research, 23: 129-134, Apr. 2003
• Nifedipine inhibits apoptotic cell death of cultured endothelial cells induced by tumor necrosis factor-alpha, (Yamagishi S), Inagaki Y, Abe R, Kikuchi S, Sasaki N, Takeuchi M, Drugs under experimental and clinical research, 29: 141-145, Apr. 2003
• Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties, (Yamagishi S), Amano S, Inagaki Y, Okamoto T, Takeuchi M, Inoue H, Microvascular research, 65: 186-190, Mar. 2003
• Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury, (Yonekura H), Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H, The Biochemical journal., 370: 1097-1109, Mar. 2003
• Glycation--a sweet tempter for neuronal death, (Kikuchi S), Shinpo K, Takeuchi M, Yamagishi S, Makita Z, Sasaki N, Tashiro K, Brain research reviews, 41: 306-323, Mar. 2003
• Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation, (Inagaki Y), Yamagishi S, Okamoto T, Takeuchi M, Amano S, Diabetologia, 46: 284-287, Feb. 2003
• Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons, (Kikuchi S), Shinpo K, Tsuji S, Takeuchi M, Yamagishi S, Makita Z, Niino M, Yabe I, Tashiro K, Brain research., 964: 228-236, Feb. 2003
• Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation, (Yamagishi S), Amano S, Inagaki Y, Okamoto T, Inoue H, Takeuchi M, Choei H, Sasaki N, Kikuchi S, Drugs under experimental and clinical research, 29: 75-80, Feb. 2003
• Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells, (Yamagishi S), Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, Kidney international., 63: 464-473, Feb. 2003
• Serum leveles of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes, (Miura J), Yamagishi S, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z, Iwamoto Y, Journal of diabetes and its complications., 17: 16-21, Jan. 2003
• Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin, (Okamoto T), Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, Takeuchi M, Ohno S, Yoshimura A, Makita Z, The FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 16: 1928-1930, Dec. 2002
• Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes, (Amano S), Yamagishi S, Kato N, Inagaki Y, Okamoto T, Makino M, Taniko K, Hirooka H, Jomori T, Takeuchi M, Biochemical and biophysical research communications, 299: 183-188, Nov. 2002
• CS-866, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats, (Koga K), Yamagishi S, Takeuchi M, Inagaki Y, Amano S, Okamoto T, Saga T, Makita Z, Yoshizuka M, Molecular medicine (Cambridge, Mass.), 8: 591-599, Nov. 2002
• Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes, (Petrova R), Yamamoto Y, Muraki K, Yonekura H, Sakurai S, Watanabe T, Li H, Takeuchi M, Makita Z, Kato I, Takasawa S, Okamoto H, Imaizumi Y, Yamamoto H, Journal of molecular and cellular cardiology., 34: 1425-1431, Oct. 2002
• Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro, (Okamoto T), Yamagishi S, Inagaki Y, Amano S, Takeuchi M, Kikuchi S, Ohna S, Yoshimura A, Biochemical and biophysical research communications, 297: 419-424, Sep. 2002
• Beraprost sodium, a prostaglandin I2 analogue, protects against advanced glycation end products-induced injury in cultured retinal pericytes, (Yamagishi S), Amano S, Inagaki Y, Okamoto T, Takeuchi M, Makita Z, Molecular medicine (Cambridge, Mass.), 8: 546-550, Sep. 2002
• Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties, (Yamagishi S), Inagaki Y, Amano S, Okamoto T, Takeuchi M, Makita Z, Biochemical and biophysical research communications, 296: 877-882, Aug. 2002
• Aminoguanidine pyridoxal adduct is superior to aminoguanidine for preventing diabetic nephropathy in mice., (Miyoshi H), Taguchi T, Sugiura M, Takeuchi M, Yanagisawa K, Watanabe Y, Miwa I, Makita Z, Koike T, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 34: 371-377, Jul. 2002
• Dilazep hydrochloride, an antiplatelet drug, prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats, (Yamagishi S), Koga K, Inagaki Y, Amano S, Okamoto T, Takeuchi M, Drugs under experimental and clinical research, 28: 221-227, Jun. 2002
• Detection of N epsilon-(carboxymethyl)lysine (CML) and non-CML advanced glycation end-products in the anterior horn of amyotrophic lateral sclerosis spinal cord, (Kikuchi S), Shinpo K, Ogata A, Tsuji S, Takeuchi M, Makita Z, Tashiro K, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 3: 63-68, Jun. 2002
• Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques, (Sasaki N), Takeuchi M, Choei H, Kikuchi S, Hayashi Y, Nakano N, Ikeda H, Yamagishi S, Kitamoto T, Saito T, Makita Z, Neuroscience letters., 326: 117-120, Jun. 2002
• Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human cultured mesangial cells, (Yamagishi S), Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, Makita Z, The Journal of biological chemistry., 277: 20309-20315, Jun. 2002
• Up-regulation of vascular endothelial growth factor and down-regulation of pigment epithelium-derived factor messenger ribonucleic acid levels in leptin-exposed cultured retinal pericytes, (Yamagishi S), Inagaki Y, Amano S, Okamoto T, Takeuchi M, International journal of tissue reactions, 24: 137-142, Apr. 2002
• Palmitate-induced apoptosis of microvascular endothelial cells and pericytes, (Yamagishi S), Okamoto T, Amano S, Inagaki Y, Koga K, Choei H, Sasaki N, Kikuchi S, Takeuchi M, Makita Z, Molecular medicine (Cambridge, Mass.), 8: 179-184, Apr. 2002
• Effect of geranylgeranylaceton on cellular damage induced by proteasome inhibition in cultured spinal neurons, (Kikuchi S), Shinpo K, Takeuchi M, Tsuji S, Yabe I, Niino M, Tashiro K, Journal of neuroscience research., 69: 373-381, Mar. 2002
• Serum levels of glucose-derived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction, (Koga K), Yamagishi S, Okamoto T, Inagaki Y, Amano S, Takeuchi M, Makita Z, International journal of clinical pharmacology research, 22: 13-17, Jan. 2002
• Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes, (Yamagishi S), Amano S, Inagaki Y, Okamoto T, Koga K, Sasaki N, Yamamoto H, Takeuchi M, Makita Z, Biochemical and biophysical research communications, 290: 973-978, Jan. 2002
• Immunological detection of a novel advanced glycation end-product, Takeuchi M, Yanase Y, Matsuura N, Yamagishi S, Kameda Y, Bucala R, Makita Z, Molecular medicine (Cambridge, Mass.), 7: 783-791, Nov. 2001
• Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice, (Yamamoto Y), Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H, The Journal of clinical investigation, 108: 261-268, Jul. 2001
• Effect of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy, (Wada R), Nishizawa Y, Yagihashi N, Takeuchi M, Ishikawa Y, Yasumura K, Nakano M, Yagihashi S, European journal of clinical investigation, 31: 513-520, Jun. 2001
• Alternative routes for the formation of immunochemically distinct advanced glycation end-products in vivo, Takeuchi M, Makita Z, Current molecular medicine, 1: 305-315, Jun. 2001
• Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy, (Endo M), Yanagisawa K, Tsuchida K, Okamoto T, Matsushita T, higuchi M, Matsuda A, Takeuchi M, Makita Z, Koike T, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 33: 317-322, May 2001
• Can we identify genes for susceptibility to diabetic microangiopathies using stroke-prone spontaneously hypertensive rat models?, (Yamagishi S), Takeuchi M, Unoki H, Medical hypotheses, 56:510-512, Apr. 2001
• Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer’s disease, (Sasaki N), Toki S, Choei H, Saito T, Nakano N, Hayashi Y, Takeuchi M, Makita Z, Brain research., 888: 256-262, Jan. 2001
• Advanced glycation end products and the pathogenesis of diabetic nephropathy., (Yamagishi S), Takeuchi M, Makita Z, Contributions to nephrology, 134:30-35, 2001
• Neurotoxicity of advanced glycation end-products for cultured cortical neurons, Takeuchi M, Bucala R, Suzuki T, Ohkubo T, Yamagzaki M, Koike T, Kameda Y, Makita Z, Journal of neuropathology and experimental neurology., 59: 1094-1105, Dec. 2000
• Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo, Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y, Molecular medicine (Cambridge, Mass.), 6: 114-125, Feb. 2000
• Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients, Takeuchi M, Makita Z, Yanagisawa K, Kameda Y, Koike T, Molecular medicine (Cambridge, Mass.), 5: 393-405, Jun. 1999
• Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients., (K.Yanagisawa), Z.Makita, K.Shiroshita, T.Fusegawa, S.Kuwajima, M.Takeuchi, T.Koike, Metabolism: clinical and experimental, 47:1348-1353, Nov. 1998
• Preparation and biological activity of manno- and galacto-validamines, new 5a-carba-glycosylamines as α-glycosidase inhibitors., (Kameda Y), Kawashima K, Takeuchi M, Ikeda K, Asano N, Matsui K, Carbohydrate research, 300:259-264, 1997
• Interactions of Escherichia coli endonuclease IV and exonuclease III with abasic sites in DNA., Takeuchi M, Lillis R, Demple B, Takeshita M, The Journal of biological chemistry., 269:21907-21914, 1994
• Trehalase inhibitors, validoxylamine A and related compounds as insecticides., (Asano N), Takeuchi M, Kameda Y, Matsui K, Kono Y, The Journal of antibiotics, 43:722-726, 1990
• Purification and some properties of cytochrome c550 from Flavobacterium saccharophilum., Takeuchi M, Matsui K, Biological & pharmaceutical bulletin, 38:1098-1099, 1990
• Inhibitory effect of validamine, valienamine, and valiolamine on activities of carbohydrases in rat small intestinal brush border membranes., Takeuchi M, Takai N, Asano N, Kameda K, Matsui K, Biological & pharmaceutical bulletin, 38:1970-1972, 1990
• Inhibitory effect of pseudo-aminosugars on oligosaccharide glucosidases I and II and on lysosomal α-glucosidase from rat liver., Takeuchi M, Kamata K, Yoshida M, Kameda Y, Matsui K, Journal of biochemistry., 108:42-46, 1990
• Chemical modification by 2,4,6-trinitrobenzene-sulfonic acid (TNBS) of an essential amino groups in 3-ketovalidoxylamine A C-N lyase., Takeuchi M, Neyazaki K, Matsui K, Biological & pharmaceutical bulletin, 38:1419-1420, 1990
• Preparation of 3-amino-3-deoxy derivatives of trehalose and sucrose and their activities., (Asano N), Katayama K, Takeuchi M, Furumoto T, Kameda K, Matsui K, The Journal of antibiotics, 42:585-590, 1989
• Purification and properties of soluble D-glucoside 3-dehydrogenase from Flavobacterium saccharophilum., Takeuchi M, Asano N, Kameda Y, Matsui K, Bioscience, biotechnology, and biochemistry, 52:1905-1912, 1988
• Physiological role of glucoside 3-dehydrogenase and cytochrome c551 in the sugar oxidizing system of Flavobacterium saccharophilum., Takeuchi M, Asano N, Kameda Y, Matsui K, Journal of biochemistry., 103:938-943, 1988
• Fluorometric studies on the role of calcium in substrate binding to 3-ketovalidoxylamine A C-N lyase., Takeuchi M, Asano N, Kameda Y, Matsui K, Biological & pharmaceutical bulletin, 36:3540-3545, 1988
• Purification and properties of glucoside 3-dehydrogenase from Flavobacterium Saccharophilum., Takeuchi M, Ninomiya K, Kawabata K, Asano N, Kameda Y, Matsui K, Journal of biochemistry., 100:1049-1055, 1986
• Chemical modification by diethylpyrocarbonate of an essential histidine residues in 3-ketovalidoxylamine A C-N lyase., Takeuchi M, Asano N, Kameda Y, Matsui K, Journal of biochemistry., 99:1571-1577, 1986
• Purification and properties of 3-ketovalidoxylamine A C-N lyase from Flavobacterium saccharophilum., Takeuchi M, Asano N, Kameda Y, Matsui K, Journal of biochemistry., 98:1631-1638, 1985
• Epivaliolamine and deoxyvalidamine, new pseudo-aminosugars produced by Streptomyces hygroscopicus., (Kameda Y), Asano N, Takeuchi M, Yamaguchi T, Matsui K, Horii S, Fukase H, The Journal of antibiotics, 38:1816-1818, 1985
• Valiolamine, a new α-glucosidase inhibiting aminocyclitol produced by Streptomyces hygroscopicus., (Kameda Y), asano N, Yoshikawa M, Takeuchi M, Yamaguchi T, Matsui K, Horii S, Fukase H, The Journal of antibiotics, 37:1301-1307, 1984
• Studies on cation-induced membrane vesicle aggregation of porcine intestinal brush borders., (Ohyashiki T), Takeuchi M, Mohri T, Journal of biochemistry., 95:881-886, 1984
• Microbial degradation of validamicin A by Flavobacterium saccharophilum－Enzymatic cleavage of C-N linkage in validoxylamine A－., (Asano N), Takeuchi M, Ninomiya K, Kameda Y, Matsui K, The Journal of antibiotics, 37:859-867, 1984
• A conformation change of the porcine intestinal calcium binding protein on binding of Ca2+., (Chiba K), Takeuchi M, Mohri T, Ohayshiki T, Biological & pharmaceutical bulletin, 31:966-970, 1983
• Temperature-induced transitions of porcine intestinal brush border membranes., (Ohyashiki T), Takeuchi M, Kodera M, Mohri T, Biochimica et biophysica acta-molecular and cell biology of lipids, 688:16-22, 1982
• Protective Effects of Collagen Tripeptides in Human Aortic Endothelial Cells by Restoring ROS-Induced Transcriptional Repression, Hidehito Saito-Takatsuji, Yasuo Yoshitomi, Yasuhito Ishigaki, Shoko Yamamoto, Noriaki Numata, Yasuo Sakai, Masayoshi Takeuchi, Naohisa Tomosugi, Shogo Katuda, hideto Yonekura, Takayuki Ikeda, Nutrients, 13:2226, Jun. 2021
• Accumulation of toxic advanced glycation end-products induces cytotoxicity and inflammation in hepatocyte-like cells differentiated from human induced pluripotent stem cells., (Kikuchi C), Sakasai-Sakai A, Okimura R, Tanaka H, Takata T, Takeuchi M, Matsunaga T, Biol. Pharm. Bull., 44:1399-1402, Oct. 2021
• Serum levels of 1,5-anhydroglucitol and 1,5-anhydrofructose-derived advanced glycation end products in patients undergoing hemodialysis., (Tanaka K), Sakasai-Sakai A, Motomiya Y, Yoneda T, Takeuchi M, 13:85, Aug. 2021
• Intracellular toxic AGEs (TAGE) triggers numerous types of cell damage., Takeuchi M, Sakasai-Sakai A, Takata T, Takino J, Koriyama Y, Furukawa A, Kikuchi C, Nagamine K, Hori T, Matsunaga T, Biomolecules, 11:387, Mar. 2021
• Suppression of hepatic stellate cell death by toxic advanced glycation end-products., (Takino J), Sato T, Nagamine K, Sakasai-Sakai A, Takeuchi M, Hori T, Biol. Pharm. Bull., 44:112-117, Jan. 2021
• RasGRP2 inhibits glyceraldehyde-derived toxic advanced glycation end-products from inducing permeability in vascular endothelial cells., (Takino J), Sato T, Kanetaka T, Okihara K, Nagamine K, Takeuchi M, Hori T, Sci. Rep., 11:2959, Feb. 2021
• Trapa bispinosa Roxb. extract lowers advanced glycation end-products and increases live births in older patients with assisted reproductive technology: a randomized controlled trial., (Jinno M), Nagai R, Takeuchi M, Watanabe A, Teruya K, Sugawa H, Hatakeyama N, Jinno Y, Reprod. Biol. Endocrinol., 19:149, Sep. 2021
• Intracellular Toxic Advanced Glycation End-Products in 1.4E7 Cell Line Induce Death with Reduction of Mirotubule-Associated Protein 1 Light Chain 3 and p62, Takanobu Takata, Akiko Sakasai-Sakai, Masayoshi Takeuchi, 14:332, Jan. 2022
• Intracellular Toxic Advanced Glycation End-Products May Induce Cell Death and Suppress Cardiac Fibroblasts, Takanobu Takata, Akiko Sakasai-Sakai, Masayoshi Takeuchi, 12:615, Jul. 2022
• Effects of Toxic AGEs (TAGE) on Human Health, Masayoshi Takeuchi, Akiko Sakasai-Sakai, Takanobu Takata, 11:2178, Jul. 2022
• Pyridoxamine and aminoguanidine attenuate the abnormal aggregation of β-tubulin and suppression of neurite outgrowth by glyceraldehyde-derived toxic advanced glycation end-products., 13:　, Jun. 2022
• The association between accumulation of toxic advanced glycation end-products and cytotoxic effect in MC3T3-E1 cells., 14:990, Feb. 2022
• Effects of toxic AGEs (TAGE) on human health., 11:2178, Jul. 2022

Books etc

• Role of advanced glycation end products (AGEs) in cell growth and death
  Focus on Cell Apoptosis Research, Daniel W. Cho eds.,
  (Yamagishi S), Nakamura K, Matsui T, Inoue H, Makino T, Shimizu T, Takeuchi M
  Nova Science  2006
• Pericytes and angiogenesis
  Progress in angiogenesis research
  (Yamagishi S), Inagaki Y, Nakamura K, Takeuchi M, Imaizumi T
  Nova Science  2004